Eli Lilly stock surged after its next-generation weight loss drug posted record results
Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, Lilly said
Overview
Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, Lilly said
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
